Using the right study materials can help strengthen the skills required to crack technical interviews in 2026. They aid in strengthening problem-solving skills, ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.85, moving -3.27% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.33%. On ...

AI startup Anthropic's claim of automating COBOL modernization sent IBM's stock plummeting, wiping billions off its market value. The decades-old language, still powering critical systems, faces a ...

Malware is evolving to evade sandboxes by pretending to be a real human behind the keyboard. The Picus Red Report 2026 shows 80% of top attacker techniques now focus on evasion and persistence, ...

The story of GraalVM in early 2026: a project settling into a quarterly cadence, tightening its support matrix, and—thanks to Oracle—being very explicit about what it is no longer going to be.

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...